A new device to prop open heart arteries after interventions to unclog them adapts over time to allow restoration of the ...

Elixir Medical's DynamX bioadaptor, introduced as a potential game-changer in heart artery treatments, adapts over time to restore the artery's natural motion. A study showed it leads to fewer ...

The FDA rejected sotagliflozin 5 years ago for the same indication but for the broader population of adults with T1D, due to ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

David J. Phillip/AP The list includes medications for type 2 diabetes, allergic diseases, chronic kidney disease, heart ...

President Joe Biden has torn into his predecessor, suggesting that international leaders are terrified of what Donald Trump's ...

Our model estimate for Zepbound is $1.5 billion. Higher demand and volume growth for Lilly’s key growth drugs like Emgality, Jardiance, Olumiant, Retevmo, Taltz and Verzenio are likely to have ...